{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T09:56:05Z","timestamp":1709373365624},"reference-count":0,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[1997,1,1]],"date-time":"1997-01-01T00:00:00Z","timestamp":852076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Diseases in Obstetrics and Gynecology"],"published-print":{"date-parts":[[1997]]},"abstract":"<jats:p><jats:italic>Objective:<\/jats:italic>The safety and efficacy of ampicillin plus sulbactam were compared with those of cefoxitin in the treatment of women with pelvic inflammatory disease (PID).<\/jats:p><jats:p><jats:italic>Methods:<\/jats:italic>This single-site, randomized, prospective, third-party-blinded, comparative, parallel-treatment study enrolled 93 women with a diagnosis of PID. Patients were treated with either ampicillin\/sulbactam (2 g\/1 g, administered intravenously [IV], every 6 h) or cefoxitin (2 g, administered IV, every 6 h) for a minimum of 12 doses. Patients with cultures positive for<jats:italic>Chlamydia trachomatis<\/jats:italic>also received concurrent oral or IV doxycycline (100 mg twice daily). Patients with cultures negative for<jats:italic>C. trachomatis<\/jats:italic>received prophylactic oral doxycycline (100 mg twice daily) for 10\u201314 days after treatment with either ampicillin\/sulbactam or cefoxitin was completed.<\/jats:p><jats:p><jats:italic>Results:<\/jats:italic>Ninety-three patients were entered in the study: 47 in the ampicillin\/sulbactam arm and 46 in the cefoxitin arm. All 93 patients were evaluable for safety; 61 (66%) were evaluable for efficacy. Demographic characteristics were similar for the groups. Of the 27 evaluable ampicillin\/sulbactam-treated patients, 67% experienced clinical cure, 30% improved, and 4% failed treatment. Respective values for the 34 cefoxitin-treated patients were 68%, 24%, and 9% (<jats:italic>P<\/jats:italic>= 0.67). Pathogens were eradicated in 70% of the women given ampicillin\/sulbactam vs. 56% of those who received cefoxitin (<jats:italic>P<\/jats:italic>= 0.64).<\/jats:p><jats:p><jats:italic>Conclusions:<\/jats:italic>Overall, ampicillin\/sulbactam demonstrated clinical and bacteriologic efficacy at least equivalent to that of cefoxitin in the treatment of women with acute PID. The use of ampicillin\/sulbactam for this indication may avoid the complex dosing regimens associated with other treatments.<\/jats:p>","DOI":"10.1155\/s1064744997000562","type":"journal-article","created":{"date-parts":[[2007,3,7]],"date-time":"2007-03-07T08:01:59Z","timestamp":1173254519000},"page":"319-325","source":"Crossref","is-referenced-by-count":2,"title":["Ampicillin\/Sulbactam Vs. Cefoxitin for the Treatment of Pelvic Inflammatory Disease"],"prefix":"10.1155","volume":"5","author":[{"given":"Joseph G.","family":"Jemsek","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Charlotte Memorial Hospital, Charlotte, NC, USA"},{"name":"Nalle Clinic, 1918 Randolph Road, Charlotte, NC 28207, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Charlotte Memorial Hospital, Charlotte, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","container-title":["Infectious Diseases in Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/idog\/1997\/183847.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/idog\/1997\/183847.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T15:05:30Z","timestamp":1507647930000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/idog\/1997\/183847\/abs\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1997]]}},"alternative-id":["183847"],"URL":"https:\/\/doi.org\/10.1155\/s1064744997000562","relation":{},"ISSN":["1064-7449","1098-0997"],"issn-type":[{"value":"1064-7449","type":"print"},{"value":"1098-0997","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997]]}}}